Diagnosis dan Tatalaksana Asthma-COPD Overlap Syndrome (ACOS)
DOI:
https://doi.org/10.55175/cdk.v47i3.342Kata Kunci:
Asthma-COPD overlap syndrome, bronkodilator kerja panjang, kortikosteroid inhalasi, spirometriAbstrak
Asthma-COPD overlap syndrome (ACOS) adalah penyakit yang ditandai dengan hambatan aliran udara persisten dengan beberapa manifestasi klinis yang biasanya berhubungan dengan asma dan penyakit paru obstruksi kronis (PPOK). ACOS diidentifikasi secara klinis bila memiliki manifestasi asma dan PPOK. Pemeriksaan spirometri menunjukkan hambatan aliran udara ekspirasi yang tidak sepenuhnya reversibel. Pengobatan ACOS adalah dengan kortikosteroid inhalasi dosis kecil atau sedang dan terapi tambahan dengan bronkodilator kerja panjang.
Asthma-COPD overlap syndrome (ACOS) is characterized by persistent airflow limitation with several features usually associated with asthma and with chronic obstructive pulmonary disease (COPD). ACOS is identified by the shared features of both asthma and COPD. Spirometry demonstrates expiratory airflow limitation that is not completely reversible. Treatment is with low or moderate dose inhaled corticosteroid and add-on long-acting bronchodilators.
Unduhan
Referensi
Bujarski S, Parulekar AD, Sharafkhaneh A, Hanania NA. The asthma COPD overlap syndrome (ACOS). Curr Allergy Asthma Rep [Internet]. 2015 Mar [cited 2019 Jun 10];15(3). Available from: http://link.springer.com/10.1007/s11882-014-0509-6
Global Initiative for Asthma. Global strategy of asthma management and prevention. Updated 2018. Vancouver, USA: GINA; 2018.
Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management and prevention of chronic obstructive pulmonary disease (2019 Report). Vancouver, USA: GOLD; 2019.
Kementerian Kesehatan RI. Hasil utama riskesdas 2018. Jakarta: Badan Penelitian dan Pengembangan Kesehatan; 2018.
Adeloye D, Chua S, Lee C, Basquill C, Papana A, Theodoratou E, et al. Global and regional estimates of COPD prevalence: Systematic review and meta–analysis. J Glob Health [Internet]. 2015 Dec [cited 2019 Jun 10];5(2). Available from: http://www.jogh.org/documents/issue201502/ jogh-05-020415.pdf
Global Initiative for Asthma. Diagnosis and initial treatment of asthma, COPD and asthma-COPD overlap (ACO): A joint project of GINA and GOLD. In: Global strategy of asthma management and prevention. Updated 2018. Vancouver, USA: GINA; 2018.
Kauppi P, Kupiainen H, Lindqvist A, Tammilehto L, Kilpeläinen M, Kinnula VL, et al. Overlap syndrome of asthma and COPD predicts low quality of life. J Asthma. 2011;48(3):279–85.
Leung JM, Sin DD. Asthma-COPD overlap syndrome: Pathogenesis, clinical features, and therapeutic targets. BMJ. 2017;358:j3772.
Tilp C, Bucher H, Haas H, Duechs MJ, Wex E, Erb KJ. Effects of conventional tobacco smoke and nicotine-free cigarette smoke on airway inflammation, airway remodelling and lung function in a triple allergen model of severe asthma. Clin Exp Allergy. 2016;46(7):957–72.
Kottyan LC, Collier AR, Cao KH, Niese KA, Hedgebeth M, Radu CG, et al. Eosinophil viability is increased by acidic pH in a cAMP- and GPR65-dependent manner. Blood. 2009;114(13):2774–82.
Hikichi M, Hashimoto S, Gon Y. Asthma and COPD overlap pathophysiology of ACO. Allergol Int. 2018;67(2):179–86.
Xuan W, Peat JK, Toelle BG, Marks GB, Berry G, Woolcock AJ. Lung function growth and its relation to airway hyperresponsiveness and recent wheeze: Results from a longitudinal population study. Am J Respir Crit Care Med. 2000;161(6):1820–4.
Postma DS, Bush A, van den Berge M. Risk factors and early origins of chronic obstructive pulmonary disease. The Lancet. 2015;385(9971):899–909.
Sin DD, Miravitlles M, Mannino DM, Soriano JB, Price D, Celli BR, et al. What is asthma−COPD overlap syndrome? Towards a consensus definition from a round table discussion. Eur Respir J. 2016;48(3):664–73.
Maselli DJ, Hardin M, Christenson SA, Hanania NA, Hersh CP, Adams SG, et al. Clinical approach to the therapy of asthma-COPD overlap. Chest. 2019;155(1):168–77.
Nixon J, Newbold P, Mustelin T, Anderson GP, Kolbeck R. Monoclonal antibody therapy for the treatment of asthma and chronic obstructive pulmonary disease with eosinophilic inflammation. Pharmacol Ther. 2017;169:57–77.
Tat TS, Cilli A. Omalizumab treatment in asthma-COPD overlap syndrome. J Asthma. 2016;53(10):1048–50.
Martinez FJ, Calverley PMA, Goehring UM, Brose M, Fabbri LM, Rabe KF. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): A multicentre randomised controlled trial. The Lancet. 2015;385(9971):857–66.
Martinez FJ, Rabe KF, Sethi S, Pizzichini E, McIvor A, Anzueto A, et al. Effect of roflumilast and inhaled corticosteroid/long-acting 2 -agonist on chronic obstructive pulmonary disease exacerbations (RE 2 SPOND). A randomized clinical trial. Am J Respir Crit Care Med. 2016;194(5):559–67.
Meltzer EO, Chervinsky P, Busse W, Ohta K, Bardin P, Bredenbröker D, et al. Roflumilast for asthma: Efficacy findings in placebo-controlled studies. Pulm Pharmacol Ther. 2015;35:20–7.
Culic O, Erakovic V, Cepelak I, Barišic K, Brajša K, Ferencic Ž, et al. Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects. Eur J Pharmacol. 2002;450(3):277–89.
Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JAD, Criner GJ, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365(8):689–98.
Gibson PG, Yang IA, Upham JW, Reynolds PN, Hodge S, James AL, et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): A randomised, double-blind, placebo-controlled trial. Lancet. 2017;390(10095):659–68.
National Asthma Council Australia. Managing asthma-COPD overlap. In: Australian Asthma Handbook. 2.0. Melbourne: National Asthma Council Australia; 2019.
Unduhan
Diterbitkan
Cara Mengutip
Terbitan
Bagian
Lisensi
Hak Cipta (c) 2020 Cermin Dunia Kedokteran
Artikel ini berlisensi Creative Commons Attribution-NonCommercial 4.0 International License.
